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Non-competitive NMDA receptor antagonists are known to induce psychosis-like symptoms in rodents.
Administration of such compounds cause behavioural effects such as memory impairment and hyper-
locomotion. Additionally, drugs such as phencyclidine (PCP), ketamine and MK-801 all cause distinctive
increases in striatal local field potential (LFP) in the high frequency oscillation (HFO) band in the power
spectrum (140e180 Hz). Amperometric sensors provide a means to measure tissue oxygen (tO2; a BOLD-
like signal) in the brains of freely-moving rats while simultaneously acquiring LFP using the same
electrode. Carbon paste electrodes were implanted into the striatum and hippocampus of male Wistar
rats. Rats were administered with saline, ketamine (10 mg/kg), MK-801 (0.1 mg/kg) and PCP (2.5 mg/kg)
and recordings were made at 1 kHz using three different potentials (650 mV to measure tO2; 0 mV
and þ700 mV as control conditions). NMDA receptor antagonism caused significant increases in tO2 in
both the striatum and the hippocampus. Power spectrum analysis showed significant increases in HFO
power in the striatum but not in the hippocampus. Conversely, there were significant decreases in delta
and alpha power along with increases in theta and gamma power in the hippocampus that were absent
in the striatum. This supports findings that LFP can be obtained from an amperometric sensor signal;
allowing simultaneous acquisition of two translational biomarkers of neuronal activity (LFP and tO2).
© 2017 Elsevier Ltd. All rights reserved.1. Introduction
The N-methyl-D-aspartate glutamate receptor (NMDA-R) is
firmly implicated in normal physiological processes such as syn-
aptic plasticity and learning along with being implicated in
diseased and disordered states such as excitotoxicity and schizo-
phrenia. Indeed, non-competitive NMDA-R antagonists are
routinely used to model schizophrenia in rodents (Neill et al., 2014;
Janhunen et al., 2015). Additionally, given the use of non-
competitive NMDA-R antagonists in humans as medical in-
terventions (ketamine) and as drugs of abuse (phencyclidine; PCP),
it is important to understand the neurophysiological effects of
these drugs to find new clinical uses for existing drugs liketics, Trinity College Dublin,ketamine and to design novel antipsychotic and antidepressant
compounds with fewer side effects and greater therapeutic value.
In rodents, it has been demonstrated that non-competitive
NMDA-R antagonists can induce characteristic changes in electro-
physiological measurements in various brain regions. The three
classic non-competitive antagonists, ketamine, PCP and MK-801, all
alter multiple frequencies of the local field potential (LFP) signal in
multiple regions in a dose-dependent manner (for a comprehen-
sive review, see Hunt and Kasicki, 2013). Notably, these drugs are
associated with increases in striatal high-frequency oscillations
(HFOs; Hunt et al., 2006, 2011) and in hippocampal gamma power
(Ma and Leung, 2000; Ehrlichman et al., 2009; Lazarewicz et al.,
2010; Hunt et al., 2011; Saunders et al., 2012).
Attempts at using functional magnetic resonance imaging
(fMRI) to directly compare changes in brain activity between ani-
mals and humans have been made but are limited by the need to
anaesthetise or sedate animals, thus introducing a confounding
factor when interpreting data (Hodkinson et al., 2012). Even so,
Abbreviations
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NMDA-R antagonists are associated with increased regional cere-
bral blood volume in the striatum (Gozzi et al., 2008a, 2008b;
Broberg et al., 2013) and hippocampus (Gozzi et al., 2008a,
2008b) as well as increases in the blood-oxygen-level-dependent
(BOLD) signal in the striatum and hippocampus (Littlewood et al.,
2006; Chin et al., 2011).
Therefore, it is desirable to develop techniques that offer greater
translational validity to make better-informed interpretations of
data generated in animal models. Amperometry is of particular
interest as it is possible to measure changes that are comparable to
imaging techniques routinely used in humans (BOLD and EEG; see
Lowry et al., 2010; Zhang et al., 2009) and can be used in freely-
moving animals With electrochemical sensors, it is possible to
measure real-time changes in tissue oxygen (tO2) in the brain with
high spatial resolution (Bolger and Lowry, 2005; Bolger et al., 2011a,
2011b) and this tO2 signal correlates highly with changes in the
BOLD signal acquired simultaneously (Lowry et al., 2010). This
permits researchers to utilise tO2 measurements as a surrogate for
fMRI in rodents, allowing for pharmacological (Kealy et al., 2013,
2015) and behavioural (McHugh et al., 2011) studies to be per-
formed in awake rodents.
Furthermore, it has been demonstrated by recording LFP while
simultaneously measuring changes in choline using an ampero-
metric sensor that the amperometric signal is made up of a low
frequency component (<1 Hz) corresponding to neurochemical
changes and a higher frequency component (>1 Hz) corresponding
to LFP (Zhang et al., 2009). The aim of this study is to confirm that
the signal obtained from oxygen sensors can also be broken down
into a low frequency component corresponding directly to changes
in oxygen and a higher frequency component that corresponds to
changes in LFP. In order to test this hypothesis, we use ketamine,
PCP, and MK-801 to pharmacologically determine whether the
>1 Hz components of the tO2 signal are in fact changes in LFP. As
these drugs all induce known changes in the LFP (Hunt and Kasicki,
2013), we can assume that if the higher frequency components of
the tO2 signal are in fact related to the LFP, they will change in a
similar manner. Additionally, baseline activity and the effects of
changing oxygen levels in vivo along with control experiments
in vitrowill be examined in a similar manner to help determine the
relationship between tO2 and LFP as translational markers of
neuronal activity akin to local and scalp electrophysiological re-
cordings made in humans. Taken together, these findings will
demonstrate how amperometry can be used to measure changes in
tO2 and LFP simultaneously, allowing for detailed translational as-
sessments of neuropharmacological and behavioural interventions
to be performed.2. Materials and methods
2.1. Subjects
Male Wistar rats (250e300 g; Charles River Laboratories Inter-
national, Inc.; U.K.) were housed in a temperature-controlled fa-
cility with a 12-h light/dark cycle (lights on at 08:00) with access ad
libitum to food and water. All procedures were performed under
license in accordance with the European Commission Directive
2010/63/EU and were approved by the Maynooth University Ethics
Committee.
2.2. Data acquisition and statistical analysis
All electrochemical experiments were performed using a low
noise potentiostat (Quadstat, eDAQ, Australia). Data acquisitionwas
performed at 1 kHz using an eCorder® interface system and eDAQ
Chart software (eDAQ, Australia). Electrophysiological recordings
were made using a Micro1401 mk II data acquisition unit (Cam-
bridge Electronic Design, U.K.) and Spike2 software (CED, U.K.).
Electrophysiological recordings weremade at 10 kHz and the signal
was amplified and filtered between 0.1 Hz and 1 kHz using a
DAM50 amplifier (WPI, U.S.A.). Data was preliminarily processed in
Microsoft® Excel® 2010 before being exported to GraphPad Prism®
5.01 for statistical analysis. Data was either normalised to baseline
levels or area under the curve (AUC) analysis was performed to
quantify any observed changes in the sensor signals over time for
statistical analysis. Fast Fourier transforms (FFTs) were performed
on 1-min time bins in eDAQ Chart and resulting power spectrawere
split into five frequency bands (delta, 1e4 Hz; theta, 5e8 Hz; alpha,
9e12 Hz; gamma, 30e100 Hz; HFO, 140e180 Hz). For multiple
comparisons, repeated-measures and mixed-factorial analysis of
variance tests (ANOVAs) with Bonferroni post-hoc analysis were
used as appropriate. p < 0.05 was considered to be significant.
2.3. Working electrode preparation and surgery
Carbon paste electrodes (CPEs; O'Neill et al., 1982) were pre-
pared and in vitro calibrations were performed using constant po-
tential amperometry in a standard three-electrode glass
electrochemical cell containing 20 ml PBS at room temperature
using a saturated calomel electrode (SCE) as the reference electrode
and a bare platinumwire as the auxiliary electrode (see Lowry et al.,
1997; Kealy et al., 2013, 2015). For CPE O2 calibrations, a three-point
calibration protocol was used (0, 240, 1200 mM) using an applied
potential of 650 mV versus SCE. The current was recorded
throughout the course of each calibration and analysis was per-
formed using quiescent steady-state conditions (Kealy et al., 2013,
2015).
Animals were anaesthetised using isofluorane (4% for induction,
1.5e3.0% for maintenance; IsoFlo®, Abbott, U.K.) and placed in a
stereotaxic frame. The skull was exposed and four screws were
implanted into the skull with one doubling as the auxiliary elec-
trode. Burr holes were made for the other electrodes. Two CPEs
were implanted into each hemisphere, targeting the striatum
(þ1.7 mm A/P; ±2.5 mm M/L; 5.0 mm D/V) and dorsal hippo-
campus (4.0 mm A/P; ±3.0 mm M/L; 2.5 mm D/V). The silver
reference electrode was implanted into the left parietal lobe. All
electrodes were cemented into place (Dentalon® Plus, Heraeus-
Kulzer, Germany) and the gold contacts at the end of each elec-
trode were cemented into a six-pin Teflon® socket (Plastics One,
U.S.A.). All animals were given saline (0.9%; 3 ml/kg body weight)
and perioperative analgesia was provided (0.3 mg/kg body weight;
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recover in an incubator.
2.4. Recording procedure
Following surgery, animals were housed in Raturn® sampling
cage systems (BASi, U.S.A.). All experiments were performed in the
animal's home bowl following five days of recovery. The sensors
from each animal were connected to the potentiostat via the six-
pin Teflon® socket using a flexible screened six-core cable (Plas-
tics One, U.S.A.). Cablingwasmounted on the Raturn® bowl to allow
free movement of the animal. Movement was recorded in eDAQ
Chart using an infrared motion detector.
Baseline recordings of tO2 (applied voltage: 650 mV) were
made daily in the striatum and hippocampus (Kealy et al., 2013).
Animals were given intraperitoneal injections of saline (0.9%); MK-
801 (0.1 mg/kg; Sigma, U.K.); phencyclidine hydrochloride (PCP;
2.5 mg/kg; Department of Chemistry, Maynooth University) and
(S)-(þ)-ketamine hydrochloride (10 mg/kg; Tocris, Bio-Techne,
U.K.). One injection was given per day with a washout period of
48 h between treatments. Treatments were given in a pseudo-
random order to minimise interaction between the active com-
pounds. Baseline recordings were made for 1 h before injections
followed by a 2 h recording period. All animals were disconnected
at night and housed together to minimise stress from being singly
housed.
Recordings were also made at 0 mV (where there should be
minimal redox activity at the electrode surface; Bolger et al., 2011b)
and at þ700 mV (where ascorbic acid and other oxidisable species,
but not oxygen, are detectable; Lowry et al., 1996). Finally, re-
cordings were made using CPEs connected to a standard electro-
physiology apparatus. CPEs implanted in the striatum of each
animal were connected to the amplifier for the electrophysiological
recording device via the same cabling and housing as above and
changes in potential at the recording electrode were measured. For
these recordings, only saline and (S)-(þ)-ketamine hydrochloride
injections were administered.
3. Results
3.1. Power spectral analysis of the amperometric oxygen signal
In order to determine whether the electrochemical reaction at
the CPE active surface had any effect on frequency components
>1 Hz, in vitro calibration data was analysed using FFT analysis at
0 mM; 240 mM and 1200 mM oxygen during quiescent periods in the
oxygen calibration. There was an overall increase in power across
all frequencies in the presence of oxygen compared to 0 mM but no
differences between 240 mM and 1200 mM oxygen (Fig. 1A). This
indicates that once oxygen is present (as is the case in the brain),
the reduction of oxygen at the electrode surface should not inter-
fere with frequency components above 1 Hz.
During baseline recording in vivo, movement was associated
with increases in tO2 in both the striatum and the hippocampus
(Fig. 1B). FFT analysis was performed on 2-min time bins of the
oxygen signals recorded while animals were awake but at rest
(n¼ 10) andwhile animals were engaged in exploratorymovement
(n ¼ 10). In the striatum (Fig. 1C), there was a sharpening of the
theta peak at 8 Hz, an appearance of another peak at around
14e20 Hz and a broadband increase in gamma power (not related
to the spike at 50 Hz resulting from mains noise). Paired t-tests
comparing stationary and moving conditions (Fig. 1D) showed that
there was a significant decrease in striatal alpha (t ¼ 3.464; df ¼ 9;
p < 0.01) and a significant increase in striatal gamma (t ¼ 2.425;
df ¼ 9; p < 0.05). In the hippocampus (Fig. 1E), there were similarchanges compared to striatum. Therewas again a sharpening of the
theta peak but at a slightly lower frequency (7 Hz) along with the
appearance of another peak at around 14e17 Hz though there were
no changes in gamma power. Paired t-tests (Fig. 1F) showed that
there was a significant decrease in hippocampal alpha power
(t ¼ 2.751; df ¼ 9; p < 0.05).
To confirm that the changes observed in vivo are attributable to
changes in LFP and not changes in tO2, the same movement ex-
periments were repeated with applied potentials of 0 mV
and þ700 mV where changes in tO2 should have no effect on the
recorded currents. As such, there were no discernible changes in
current associated with movement in either the striatum or the
hippocampus at 0 mV (Fig. 2A) orþ700 mV (Fig. 2B). Power spectra
at 0 mV (n¼ 4) showed similar changes associated with movement
as observed at 650 mV in both the striatum (Fig. 2C) and hippo-
campus (Fig. 2E). Similarly, at þ700 mV, power spectra (n ¼ 6) in
the striatum (Fig. 2D) and hippocampus (Fig. 2F) were similar to
those observed at 0 and -650 mV.
3.2. Effect of non-competitive NMDA receptor antagonists on local
field potential and tO2
Following a baseline period of 10 min, animals were given an
intraperitoneal injection on different days with either saline (0.9%;
vehicle control) or a non-competitive NMDA-R antagonist (keta-
mine; PCP; MK-801). Recordings were made from the striatum and
hippocampus for 2 h post-injection and analysed post hoc in order
to extract the LFP components of the signals. Briefly, the oxygen
signals from each animal were divided into 1-min time bins and FFT
analysis was performed on them. The resulting power spectra were
divided into five frequency bands, averaged and normalised to the
baseline period. Changes in LFP power were plotted against time to
compare with changes in tO2. Following saline administration
(n¼ 15; Fig. 3A), there was a transient increase in movement and in
tO2 in both the striatum and hippocampus associated with injec-
tion stress. Changes in LFP were similarly transient with increases
in gamma power and decreases in theta and alpha power in the
striatum along with increases in theta, gamma and HFO power and
a decrease in delta power in the hippocampus.
Ketamine administration (n ¼ 15; Fig. 3B) induced hyper-
locomotion lasting approximately 35 min with an accompanying
increase in tO2 in both brain regions. These changes in tO2 were
very similar but the changes in LFP showed regional differences
with increases in gamma and HFO power and decreases in theta
and alpha power in the striatum. Whereas in the hippocampus,
there was an increase in gamma power and decreases in delta and
alpha power associated with ketamine treatment.
MK-801 administration (n ¼ 8 for striatum, n ¼ 9 for hippo-
campus; Fig. 3C) induced hyperlocomotion and an increase in tO2 in
both the striatum and the hippocampus lasting at least 120 min. In
the striatum, there was a very large increase in HFO power lasting
at least 120 min along with more moderate increases in delta and
gamma power and decreases in theta and alpha power. In the
hippocampus, there were increases in theta, gamma and HFO po-
wer along with a decrease in delta power. Alpha power showed a
phasic response with an initial decrease (0e15 min) followed by an
increase (15e40 min) before dipping below baseline again
(70e110 min).
PCP administration (n ¼ 6 for striatum, n ¼ 7 for hippocampus;
Fig. 3D) induced hyperlocomotion lasting at least 120 min. How-
ever, unlike ketamine or MK-801, tO2 levels in both regions
returned to baseline after approximately 45 min (i.e. before
hyperlocomotion wore off). In the striatum, there was a large in-
crease in HFO power and moderate increases in gamma power
whereas theta and alpha power both decreased in power together.
Fig. 1. In vitro calibration data analysed using FFT analysis at 0 mM; 240 mM and 1200 mM oxygen during quiescent periods in the oxygen calibration (A); there was an increase in
power in all frequencies in the presence of oxygen compared to 0 mM but there were no significant differences between 240 mM and 1200 mM. During baseline recording in vivo,
movement was associated with increases in tO2 in both the striatum and the hippocampus (B). Power spectra from 2-min time bins of the oxygen signals recorded in the striatum
while animals were awake but at rest (n ¼ 10) and while animals were engaged in exploratory movement (n ¼ 10) revealed a defined theta peak at 8 Hz along with a peak at around
14e20 Hz and a broadband increase in gamma power associated with movement (C). There was a significant decrease in alpha and a significant increase in gamma power in the
striatum (D). In the hippocampus, movement was associated with a sharpened theta peak at 7 Hz along with another peak at around 14e17 Hz (E). Paired t-tests revealed a
significant decrease in alpha power in the hippocampus (F). *p < 0.05; **p < 0.01; ***p < 0.001.
Fig. 2. To confirm that the changes in frequency power observed in vivo are attributable to changes in LFP and not to changes in tO2, movement experiments were repeated with
applied potentials of 0 mV and þ700 mV where there should be no contribution of tO2 to the recorded currents. There were no changes in current associated with movement in
either the striatum or the hippocampus at 0 mV (A) or þ700 mV (B). Power spectra at 0 mV (n ¼ 4) in the striatum (C) and hippocampus (E) and at þ700 mV (n ¼ 6) in the striatum
(D) and hippocampus (F) showed similar changes associated with movement as the power spectra obtained at 650 mV.
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hippocampus, there was an increase in gamma power lasting at
least 120 min though unlike MK-801, both theta and HFO power
remained at baseline levels throughout the recording period. Delta
and alpha power both showed a phasic response to PCP treatment
with an initial decrease (0e25 min) followed by an increase
(40e60 min) before dipping below baseline again (80e120 min).
In order to compare the effect of each drug treatment to eachother, AUC analysis was performed on baseline-corrected data from
the 30-min period immediately following injection and two-way
ANOVA was used to make comparisons between the effects seen
due to drug treatment and brain region on tO2 and LFP data. For tO2
recordings (Fig. 4A), there was a significant effect for drug treat-
ment (F ¼ 10.70; df ¼ 3, 69; p < 0.001) but there was no effect for
brain region (F ¼ 0.6383; df ¼ 1, 69; p > 0.05) and there was no
interaction effect (F ¼ 1.489; df ¼ 3, 69; p > 0.05). Bonferroni post
Fig. 3. Top row: Averaged tO2 recordings in the striatum and hippocampus of freely-moving rats. Middle row: Averaged frequency band powers from tO2 recordings made in the striatum. Bottom row: Averaged frequency band powers
from tO2 recordings made in the hippocampus. Changes in frequency band powers shown without SEM for clarity. Following a baseline period of 10 min, animals were given an intraperitoneal injection containing either saline (0.9%;
vehicle control) or a non-competitive NMDA-R antagonist (ketamine; PCP; MK-801). Following saline administration (n ¼ 15; A), there was a transient increase in movement along with an increase in tO2 levels in both the striatum and
hippocampus accompanied by changes in theta, alpha and gamma power in the striatum and in delta, theta, gamma and HFO power in the hippocampus. Ketamine administration (n ¼ 15; B) induced hyperlocomotion with an
accompanying increase in tO2 in both brain regions. Changes in LFP showed regional differences with increases in gamma and HFO power and decreases in theta and alpha power in the striatum compared to increases in gamma power
and decreases in delta and alpha power in the hippocampus. MK-801 administration (n ¼ 8 for striatum, n ¼ 9 for hippocampus; C) induced hyperlocomotion and an increase in tO2 in both brain regions. In the striatum, there was a
large increase in HFO power along with moderate increases in delta and gamma power and decreases in theta and alpha power. In the hippocampus, there were increases in theta, gamma and HFO power and a decrease in delta power.
PCP administration (n ¼ 6 for striatum, n ¼ 7 for hippocampus; D) induced hyperlocomotion and increased tO2 levels in both brain regions. In the striatum, there was a large increase in HFO power, moderate increases in gamma power
and decreases in delta, theta and alpha power. In the hippocampus, there was an increase in gamma power and a phasic response was observed in delta and alpha power.
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Fig. 4. AUC analysis was performed on baseline-corrected data from the 30-min period immediately following injection. For tO2 recordings (A), there were significant increases in
striatal tO2 following treatment with ketamine, MK-801 and PCP compared to saline. In the hippocampus, there were significant increases in tO2 following ketamine and MK-801
treatment compared to saline. For delta power (B), there was a significant decrease in delta power in the hippocampus following treatment with ketamine. For theta power (C),
there was a significant increase in theta power in the hippocampus following treatment with MK-801. For alpha power (D), there was a significant decrease in alpha power in the
hippocampus following treatment with ketamine. For gamma power (E), there was a significant increase in gamma power in the hippocampus following treatment with MK-801.
For HFO power (F), there was a significant increase in HFO power in the striatum following treatment with MK-801. *p < 0.05; **p < 0.01; ***p < 0.001.
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following treatment with ketamine (p < 0.05), MK-801 (p < 0.001)
and PCP (p < 0.01) compared to saline. In the hippocampus, there
were significant increases in tO2 following ketamine (p < 0.05) and
MK-801 treatment (p < 0.05) compared to saline.
For delta power (Fig. 4B), there was no significant effect for drug
treatment (F ¼ 0.5499; df ¼ 3, 59; p > 0.05) but there was a sig-
nificant effect for brain region (F ¼ 5.176; df ¼ 1, 59; p < 0.05) along
with a significant interaction effect (F ¼ 3.551; df ¼ 3, 59; p < 0.05).
Bonferroni post hoc tests showed that there was a significant
decrease in delta power in the hippocampus following treatment
with ketamine (p < 0.05). For theta power (Fig. 4C), there were no
significant effects for drug treatment (F ¼ 2.440; df ¼ 3, 62;
p > 0.05) or brain region (F ¼ 2.914; df ¼ 1, 62; p > 0.05), nor was
there an interaction effect (F ¼ 2.394; df ¼ 3, 62; p > 0.05). Bon-
ferroni post hoc tests showed that therewas a significant increase in
theta power in the hippocampus following treatment with MK-801
(p < 0.01). For alpha power (Fig. 4D), there were no significant ef-
fects for drug treatment (F ¼ 2.473; df ¼ 3, 62; p > 0.05) or brain
region (F ¼ 1.066; df ¼ 1, 62; p > 0.05), nor was there an interaction
effect (F ¼ 1.759; df ¼ 3, 62; p > 0.05). Bonferroni post hoc tests
showed that there was a significant decrease in alpha power in the
hippocampus following treatment with ketamine (p < 0.01).
For gamma power (Fig. 4E), there were significant effects for
drug treatment (F ¼ 4.055; df ¼ 3, 66; p < 0.05) and brain region
(F ¼ 6.407; df ¼ 1, 66; p < 0.05), as well as an interaction effect
(F ¼ 4.005; df ¼ 3, 66; p < 0.05). Bonferroni post hoc tests showed
that there was a significant increase in gamma power in the hip-
pocampus following treatment with MK-801 (p < 0.001). For HFO
power (Fig. 4F), there were significant effects for drug treatment
(F ¼ 3.142; df ¼ 3, 69; p < 0.05) and brain region (F ¼ 10.25; df ¼ 1,
69; p < 0.01), but there was no interaction effect (F ¼ 2.163; df ¼ 3,
69; p > 0.05). Bonferroni post hoc tests showed that there was a
significant increase in HFO power in the striatum following treat-
ment with MK-801 (p < 0.001).
To confirm that changes in these frequency bands were notrelated to changes in tO2, an applied potential of 0 mV was used.
There was no change in current following ketamine administration,
indicating that there was no contribution of tO2 to the 0 mV signal
(Fig. 5A). At 0 mV, there was a similar change in frequency bands
associated with LFP as observed at 650 mV including distinctive
increase in HFO power in the striatum (Fig. 5B) and an increase in
gamma power in the hippocampus (Fig. 5C). Finally, CPEs implan-
ted in the striatum were connected to a traditional electrophysio-
logical recording device and voltage changes were recorded with
no potential applied to the CPE at all (Fig. 5D). Ketamine adminis-
tration showed similar changes in power as it did when a voltage
was being applied to the sensor, including an increase in HFO po-
wer (Fig. 5E).
4. Discussion
This study confirms that recordings made with amperometric
sensors contain two main components: a slow, chemical-based
component (in this case attributable to oxygen) and a faster,
electrophysiological-based component (attributable to LFP; Zhang
et al., 2009). Evidence to support this finding comes from the lack
of contribution of oxygen to frequency components above 1 Hz
in vitro and the similarity of higher frequency components of the
amperometric signal recorded in vivo to recordings made with
standard electrophysiological protocols (as presented here and in
the wider literature). Using amperometric sensors in such a way
allows for increased translational validity as changes in tO2 can be
used as an analogue of BOLD activity in fMRI (Lowry et al., 2010)
while simultaneously acquiring electrophysiological information
that can be related to human electrophysiological recordings. This
enables preclinical researchers to design experiments in freely-
moving animals that better approximate human neuroimaging
studies (Francois et al., 2012, 2014; 2016), thus providing preclinical
researchers a powerful tool for understanding the relationships
between brain activity with neuropharmacological and behavioural
interventions.
Fig. 5. To confirm that changes in frequency bands relating to non-competitive NMDA receptor antagonist treatment was related to LFP and not changes in tO2, an applied potential
of 0 mV was used. Unlike at 650 mV, there was no change in current observed following ketamine administration (A). At 0 mV, there was a similar change in frequency bands
associated with LFP as was observed at 650 mV including an increase in striatal HFO power (B) and an increase in hippocampal gamma power (C). Finally, the CPEs implanted in
the striatum were used to measure LFP using a traditional electrophysiological recording protocol (D). Ketamine administration (hatched line in D) resulted in similar changes in
frequency bands associated with LFP power as it did when a voltage was being applied to the CPE, including an increase in HFO power (E).
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LFP, we demonstrate here the pharmacological effects of three non-
competitive NMDA-R antagonists on neuronal activity in the rat
brain. These compounds were used as they have been consistently
shown to modulate LFP in rodents in a known way (see Hunt and
Kasicki, 2013 for an overview). As was expected, pharmacologi-
callu induced changes in tO2 described here align with previous
work with non-competitive NMDA-R antagonists using amper-
ometry (Finnerty et al., 2013) and pharmacological MRI (Li et al.,
2014). Importantly, many of the corresponding changes in power
that were found in the LFP component of the amperometric signal
correspond with changes that been reported in the wider electro-
physiological literature. In the striatum, there were significant in-
creases in HFO power following MK-801 treatment, similar to those
seen in standard electrophysiology (Hunt et al., 2006, 2011). Non-
significant increases in HFO power were also observed following
ketamine and PCP treatment. Changes in lower frequency bands in
the striatum failed to reach significance though decreases in those
frequency bands were expected (Dimpfel and Spüler, 1990).
In the hippocampus, significant decreases in delta and alpha
power following ketamine administration were found in the
amperometric signal. MK-801 also induced a significant increase in
hippocampal theta, suggesting a peak shift down from alpha when
non-competitively blocking NMDA-Rs. A decrease in delta (Dimpfel
and Spüler, 1990) and theta power (Dimpfel and Spüler, 1990;
Pitk€anen et al., 1995; Ehrlichman et al., 2009; Lazarewicz et al.,
2010; Kittelberger et al., 2012) was expected; though for hippo-
campal theta some groups have reported no change (Leung, 1985;
Dimpfel and Spüler, 1990; Ehlers et al., 1992; Ma and Leung,
2000; Ehrlichman et al., 2009; Kittelberger et al., 2012; Saunders
et al., 2012) or an increase (Dimpfel and Spüler, 1990) following
treatment with non-competitive NMDA-R antagonists. These in-
consistencies may be explained along three lines of reasoning: 1)
Different drugs and doses appear to modulate these frequency
bands in different ways; 2) some studies measure LFP from thewhole hippocampus and others from specific hippocampal sub-
fields; and 3) lack of agreement about theta's frequency range is
commonwith most papers defining theta as 5e10 Hz as opposed to
splitting that range into 5e8 Hz for theta and 9e12 Hz for alpha.
However, the case for hippocampal gamma and HFO is more clear-
cut with the expected increase in the former and no change in the
latter found following MK-801 treatment (with non-significant
increases observed following the other two drug treatments),
contrary to the case in the striatum (Ma and Leung, 2000;
Ehrlichman et al., 2009; Lazarewicz et al., 2010; Hunt et al., 2011;
Saunders et al., 2012).
Overall, these changes largely follow the trajectories predicted
by the electrophysiological literature. The amperometric data
confirms that there are clear differences between the striatum and
hippocampus in how LFP responds to exploratory behaviour and
pharmacological intervention. Further evidence to support the
hypothesis that LFP is part of the amperometric signal can be
gleaned from the movement power spectra with hippocampal
power spectra being consistently larger than in the striatum due to
the laminar organisation of the hippocampus (Berke, 2005). Inter-
estingly, there is a less clear distinction between regions based on
the tO2 changes with significant increases in both regions observed.
Changes in tO2 (and therefore BOLD) does appear to be useful in
confirming the time courses for when an animal is moving or when
a drug is having an neurological effect as most of the pertinent
changes in LFP occur concurrently.
It is currently impossible to differentiate between changes in
power associated with tO2 (Li et al., 2014) and slow LFP oscillations
(<1 Hz; Penttonen and Buzsaki, 2003); a second LFP-only recording
electrode in close proximity to the CPE would be required to
determine any possible relationships between slow oscillatory ac-
tivity and tO2 levels. However, given that the power spectra ob-
tained from recordings made at different applied voltages and from
recordings made by using the CPEs in place of traditional electro-
physiological recording electrodes are so similar, it is possible to say
J. Kealy et al. / Neuropharmacology 116 (2017) 343e350350that the higher frequency components of the amperometric signal
are due to changes in the LFP (Zhang et al., 2009). This allows for
one set of electrodes to be used to simultaneously monitor changes
in tO2, a BOLD-like measurement (Lowry et al., 2010), with LFP, an
electrophysiological biomarker that can also be measured in
humans. As up to four electrodes can be implanted simultaneously,
it is possible to dissect functional dissociation between regions
based on pharmacological interventions and behavioural processes
with these biomarkers. This technique consequently lends itself to
drug evaluation trials by providing chronic, real-time information
that can be used to better understand the mechanisms and validity
of novel and established therapeutics with direct comparisons to
neuroimaging data from human trials.
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